Lexaria Bioscience (LEXX) Net Income towards Common Stockholders (QoQ) (2015 - 2026)
Lexaria Bioscience (LEXX) Net Income towards Common Stockholders (QoQ) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 42.86% |
| Feb 28, 2026 | -12.50% |
| Nov 30, 2025 | -40.74% |
| Aug 31, 2025 | -28.95% |
| May 31, 2025 | 40.74% |
| Feb 28, 2025 | 0.00% |
| Nov 30, 2024 | 22.73% |
| Aug 31, 2024 | 22.22% |
| May 31, 2024 | 200.00% |
| Feb 29, 2024 | -50.00% |
| Nov 30, 2023 | 0.00% |
| Aug 31, 2023 | -50.00% |
| May 31, 2023 | 84.62% |
| Feb 28, 2023 | 174.03% |
| Nov 30, 2022 | -19.66% |
| Aug 31, 2022 | 38.42% |
| May 31, 2022 | -267.13% |
| Feb 28, 2022 | 171.53% |
| Nov 30, 2021 | -69.19% |
| Aug 31, 2021 | 53.93% |